Current Support
Siolta Therapeutics, “A phase 1b/2, randomized, double-bling, placebo-controlled, multi-center study of STMC-103H in neonate and infants at risk for developing allergic disease” (2022-2040). Jackson, PI
NIH/NIAID (UM1 AI160040), “Childhood asthma in urban settings (CAUSE)” (2021-2028). Jackson, PI
NIH/NIAID & Benaroya Research Institute at Virginia Mason (U19 AI167891), “Systems immunology profiling of respiratory viral infections in vulnerable populations” (2022-2027). Jackson, Co-Investigator
OM Pharma, “A randomized, placebo-controlled, double-bling, multicenter, phase II study to assess the efficacy and safety of OM-85 versus placebo given on top of routine treatment in children aged 1-5 years with recurrent wheezing episodes) (2022-2025). Jackson, PI
Regeneron Pharmaceuticals, “Prevention of asthma exacerbations using Dupilumab in urban children and adolescents (PANDA)” (2021-2025). Jackson, PI
NIH/NIAID (R01 AI148707), “Mechanisms of enhanced neutralizing antibody responses to Rhinovirus C” (2020-2025). Jackson, Co-Investigator.
NIH/NIAID (UM2 AI130836), “New horizons in the prevention and treatment of food allergy – SUNBEAM” (2020-2024). Jackson, Co-Investigator
NIH/NHLBI (UG1 HL139118), “The great lakes PRECISE partnership” (2017-2024). Jackson, Co-Investigator
NIH/NHLBI & University of Arizona (U01 HL130045), “Oral bacterial extracts (ORBEX): Primary prevention of asthma and wheezing in children” (2016-2024). Jackson, Site PI
NIH/NIAID & Children’s Hospital of Boston (U01 AI126614), “Preventing asthma in high risk kids (PARK)” (2016-2024). Jackson, Site PI
NIH/Office of the Director (UG3 OD023282), “Children’s respiratory and environmental workgroup (CREW)” (2016-2023). Jackson, Co-Investigator
Completed Support
GlaxoSmithKline, “Mechanisms underlying asthma exacerbations prevented with and persistent despite immune-based therapy: A systems approach (MUPPITS-2)” (2017-2023). Jackson, PI
NIH/NIAID (U19 AI104317), “Viral and environmental determinants of rhinovirus illness severity” (2013-2023). Jackson, Co-Investigator
NIH/NIAID (UM1 AI114271), “The effects of allergen associated type-2 inflammation and particulate matter inflammation in the airway epithelium on SARS-CoV-2 infection” (2020-2021). Jackson, PI
NIH/NIAID (UM1 AI114271). “Inner city asthma consortium 3 (ICAC3)” (2014-2021). Jackson, PI
NIH/NIAID (UM1 AI114271). “Human epidemiology and response to SARS-CoV-2 (HEROS)” supplement to “Inner city asthma consortium 3 (ICAC3)” (2020). Jackson, PI
GlaxoSmithKline, “A long-term access programme for subjects with severe asthma who participated in a GSK-sponsored Mepolizumab clinical study” (2017-2020). Jackson, PI
NIH/NHLBI (P01 HL070831). “COAST – Rhinovirus infections in children and adolescents” (2013-2019). Jackson, PI; Lemanske, Co-PI
Pharmaxis, “Mannitol challenge in COAST” (2009-2019). Jackson, Co-Investigator
GlaxoSmithKline, “An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma” (2015-2018). Jackson, PI
NIH/NHLBI & Pennsylvania State University (U10 HL098115). “AsthmaNet: STICS protocol” (2013-2018). Jackson, Co-Investigator, STICS Protocol PI
NIH/NHLBI (U10 HL098090), “AsthmaNet: UW-Madison clinical and translational research center” (2013-2018). Jackson, Co-Investigator
NIH/NHLBI & Pennsylvania State University (U10 HL098115). “Viral determinations for AsthmaNet STICS protocol (biome & main study)” (2014-2017). Jackson, Subaward PI
NIH/NHLBI & Pennsylvania State University (U10 HL098115). “Viral determinations for AsthmaNet INFANT-AVICA protocol” (2013-2017). Jackson, Subaward PI
NIH/NHLBI & Pennsylvania State University (U10 HL098115). “Viral determinations for AsthmaNet APRIL-OCELOT protocol” (2011-2017). Jackson, Subaward PI
NIH/NIAID & University of Texas Health Science Center (U19 AI104317). “Mechanisms of enhanced enterovirus D68 pathogenicity” (2014-2016). Jackson, Opportunity Fund PI
NIH/NIAID (U19 AI104317), “Mechanisms and environmental determinants of rhinovirus illness severity” (2013-2016). Jackson, Project 1 Co-Investigator
NIH/NIAID & University of California-San Francisco (P01 AI089473). “Virus/microbe interactions and asthma” under P01 AI089473: “Pets and the infant microbiome: Effect on immune maturation & atopic asthma” (2014-2015). Jackson, Subaward PI
NIH/NCRR, NIH/NCATS & UW Institute for Clinical & Translational Research (KL2 RR025012 & KL2 TR000427). “Mechanisms linking immune dysregulation, allergy, viruses, and childhood asthma” (2010-2014). Jackson, KL2 Scholar
NIH/NCRR, NIH/NCATS & UW Institute for Clinical & Translational Research (UL1 RR025012 & UL1 TR000427), “Epithelial cell allergy-virus interactions in asthma” (2011-2013). Jackson, Pilot Grant PI
American Academy of Allergy, Asthma & Immunology (AAAI, fellow career development award). “Cytokine dysregulation, virus infections, and asthma” (2009-2011). Jackson, PI